Invention Grant
- Patent Title: Mutant NGAL proteins and uses thereof
- Patent Title (中): 突变NGAL蛋白及其用途
-
Application No.: US13684060Application Date: 2012-11-21
-
Publication No.: US09534027B2Publication Date: 2017-01-03
- Inventor: Jonathan Barasch , Andong Qiu
- Applicant: The Trustees of Columbia University in the City of New York
- Applicant Address: US NY New York
- Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
- Current Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
- Current Assignee Address: US NY New York
- Agency: Wlmer Cutler Pickering Hale and Dorr LLP
- Main IPC: C07K14/47
- IPC: C07K14/47
Abstract:
In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
Public/Granted literature
- US20130217637A1 MUTANT NGAL PROTEINS AND USES THEREOF Public/Granted day:2013-08-22
Information query
